Jim Cramer: JNJ Shouldn't Be Trading Off of its Vaccine Trial, But Rather its Earnings

Name: Jim Cramer: JNJ Shouldn't Be Trading Off of its Vaccine Trial, But Rather its Earnings
Uploaded: 2020-10-13T15:34:13+00:00
Duration: P53S
Description: Jim Cramer discusses Johnson & Johnson.

Credit: The Street

Duration: 00:53s 13 Oct 2020 0 shares 1 views